Regeneron (REGN) – FDA
-
Regeneron (REGN) Reports New Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
-
Regeneron (REGN) Reports Dupixent Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to REGN Stock Lookup